NCT06022809Completed
Comparative Effectiveness of Individual Versus Group-Level Interventions to Increase PrEP Uptake and Reduce HIV/STI Incidence
Comparative Effectiveness of Individual Versus Group-level Interventions to Reduce HIV Risk Among African Immigrant Women
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The HIV diagnosis rate among African-born Black women is the highest of all Black individuals living in the US. Correct and consistent use of condoms and use of pre-exposure prophylaxis (PrEP) are two effective means of decreasing HIV risk among women, but they remain suboptimal among Black women. The specific aims of this study are: 1. To culturally adapt two widely utilized, evidence-based HIV prevention interventions originally designed for US born Black women (Sister-to-Sister (S2S) and Sisters Informing Sisters about Topics on AIDS (SISTA)) for use by African-born women. To ensure the interventions resonated with African culture, they were given new names. The adapted S2S program was renamed as 'Dada Kwa Dada' (DKD), and the SISTA adaptation as 'DADA.' In Swahili and various other languages across East and West Africa, 'dada' means 'sister'. 2. To conduct a randomized controlled comparative effectiveness trial (RCT) to determine the effectiveness of adapted versions of S2S versus SISTA on increasing condom use and PrEP uptake among African-born women. This study compares the effectiveness of an individual versus a group-level intervention to increase pre-exposure prophylaxis (PrEP) uptake, condom use, and HIV testing and decrease the incidence of HIV and other sexually transmitted infections (STIs).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 149 (actual)
- First submitted
- 28 Aug 2023
- Start date
- Nov 2023
- Primary completion date
- Jan 2026
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- HIV
- NCT number
- NCT06022809
What you commit to
- Study type: Interventional
- Participants enrolled: 149
- From Nov 2023 to the primary completion date, Jan 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Cis-gender man, transgender woman, transgender man, Pregnant woman
Who the study is looking for
- HIV-negative
- Born in an African country
- Currently living in Greater Boston Area or New York City
- Cis-gender woman
- Self-reported Black or mixed-Black race
- Fluent in English or French
- Ages between 18 and 45
- Report of condomless vaginal or anal sex with one or more male(s) in the last 3 months prior to enrollment
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Whittier Street Health Center Coordinator of this site? Confirm its status | Roxbury | United States | Unknown status |
| Muslim Women's Insitute for Research and Development Coordinator of this site? Confirm its status | The Bronx | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.